Scientists Find Hidden Liver Protein That Slashes Bad Cholesterol
A newly discovered protein called HELZ2 controls how much harmful cholesterol the liver releases, opening a fresh path to heart disease treatment.
Summary
Researchers at UT Southwestern Medical Center have identified a protein called HELZ2 that acts as a master regulator of harmful cholesterol production in the liver. HELZ2 works by breaking down the genetic instructions needed to make apoB, the protein that forms cholesterol-carrying particles linked to clogged arteries and heart disease. When HELZ2 activity is high, fewer of these dangerous particles enter the bloodstream, reducing LDL cholesterol and triglycerides. Mice with elevated HELZ2 activity showed significantly less arterial plaque buildup. However, there is a trade-off: more fat accumulated in the liver. Published in Circulation, this discovery could eventually lead to entirely new drug targets for cardiovascular disease, operating through a mechanism distinct from existing cholesterol-lowering therapies like statins.
Detailed Summary
Heart disease remains the leading cause of death globally, and high levels of apoB-containing lipoproteins — including LDL cholesterol — are among the most established drivers of arterial plaque and cardiovascular risk. Most existing therapies target cholesterol after apoB proteins are already made. This new discovery changes that picture entirely by revealing a much earlier control point in the process.
Scientists at UT Southwestern Medical Center identified a protein called HELZ2 that regulates how long the genetic message for apoB survives inside liver cells. When HELZ2 activity increases, it accelerates the breakdown of APOB messenger RNA, meaning fewer apoB proteins are produced and fewer cholesterol-carrying lipoprotein particles enter the bloodstream. This upstream mechanism of action is novel and distinct from statins or PCSK9 inhibitors.
The team used a large-scale genetic screening platform developed by Nobel laureate Bruce Beutler to study unusual fat patterns in mice. They identified a gain-of-function HELZ2 mutation that reduced circulating LDL cholesterol and triglycerides, and importantly, provided measurable protection against atherosclerosis — the arterial plaque disease behind most heart attacks and strokes.
There is a significant caveat, however. While elevated HELZ2 activity lowered blood cholesterol, it simultaneously caused fat to accumulate in the liver, a condition associated with metabolic liver disease. This reveals a delicate physiological trade-off: the liver essentially stores fat it cannot export. Finding ways to capture HELZ2's cardiovascular benefits without increasing liver fat will be a central challenge for any future therapeutic development.
The study, published in the American Heart Association journal Circulation, is currently limited to animal models. Human translation remains years away. Still, HELZ2 represents a compelling new drug target — one that could eventually complement or improve upon existing cholesterol-lowering strategies for high-risk patients.
Key Findings
- HELZ2 protein reduces LDL cholesterol by breaking down apoB mRNA before the protein is ever produced
- Mice with elevated HELZ2 showed significantly less atherosclerotic arterial plaque compared to controls
- Higher HELZ2 activity also caused liver fat accumulation, revealing a cardiovascular versus liver fat trade-off
- This mechanism is upstream of existing drug targets like statins and PCSK9 inhibitors, suggesting novel therapy potential
- Discovery made using Nobel Prize-winning genetic screening technology at UT Southwestern Medical Center
Methodology
This is a research summary based on a peer-reviewed study published in Circulation, a high-credibility American Heart Association journal. Evidence derives from mouse genetic models including gain-of-function mutation studies and atherosclerosis plaque quantification. The screening platform was developed by Nobel Prize winner Bruce Beutler, adding methodological credibility.
Study Limitations
All findings are currently from mouse models only; human relevance has not been established. The article is a news summary, not the full primary paper, so methodological details require verification in the original Circulation publication. The liver fat accumulation side effect represents an unresolved challenge that could limit therapeutic translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.